
Cara Therapeutics (Thu, Mar 28, 2024)

Buy candidate since Mar 27, 2024 Gain 4.72%



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

score: 4.82

#/ 30145

Trend: MV Long: MV Short: Buy Volume: Buy MACD: Sell

Tech commentaries:

The Cara Therapeutics stock price gained 4.72% on the last trading day (Thursday, 28th Mar 2024), rising from \$0.87 to \$0.91. During the last trading day the stock fluctuated 12.94% from a day low at \$0.85 to a day high of \$0.96. The price has been going up and down for this period, and there has been a 15.7% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 76 thousand more shares were traded than the day before. In total, 637 thousand shares were bought and sold for approximately \$579.86 thousand.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 52.10% during the next 3 months and, with a 90% probability hold a price between \$1.12 and \$1.74 at the end of this 3-month period.

The Cara Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at \$0.86 and \$0.82. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday, March 26, 2024, and so far it has risen 24.62%. Further rise is indicated until a new top pivot has been found. Cara Therapeutics has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the priceformation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Cara Therapeutics finds support from accumulated volume at \$0.91 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at \$0.95, \$0.98 and \$1.00.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved \$0.110 between high and low, or 12.94%. For the last week, the stock has had daily average volatility of 13.17%.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Cara Therapeutics stock to perform well in the short-term.

Risk: High

Evaluation: Buy Candidate